Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
暂无分享,去创建一个
Hans Clevers | John W. M. Martens | Stephen P. Ethier | Mieke Schutte | John A. Foekens | Justine K. Peeters | Antoinette Hollestelle | Pim J. French | Winand N. M. Dinjens | J. Foekens | J. Klijn | M. Riaz | A. Hollestelle | M. Smid | J. Martens | S. Ng | M. Schutte | H. Clevers | M. Rozendaal | W. Dinjens | E. Zwarthoff | A. Jochemsen | A. Teunisse | S. Lam | S. Ethier | P. French | J. Peeters | T. T. ten Hagen | J. Nagel | Jan G. M. Klijn | Marcel Smid | Fons Elstrodt | F. Elstrodt | Marijke Wasielewski | D. G. Koopman | Bertie H. C. G. M. Leeuw | Peter J. Spek | M. A. Bakker | Aart G. Jochemsen | Marijke Wasielewski | Ser Sue Ng | Ellen C. Zwarthoff | Timo L. M. ten Hagen | Amina Teunisse | Suzanne Lam | Jord H. A. Nagel | Marieke J. Rozendaal | Muhammad Riaz | Daphne G. Koopman | Michael A. Bakker | M. Bakker | T. L. T. ten Hagen | P. Spek | Marieke Rozendaal
[1] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[2] M. Skolnick,et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. , 1997, Cancer research.
[3] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[4] J. Minna,et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.
[5] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[6] S. Jeffrey,et al. Basal carcinoma of the breast revisited: an old entity with new interpretations , 2008, Journal of Clinical Pathology.
[7] A. Børresen-Dale,et al. TP53 and breast cancer , 2003, Human mutation.
[8] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[10] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[11] Mieke Timmermans,et al. How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study , 2005, Clinical Cancer Research.
[12] S. Sukumar,et al. Mutations in p53 as potential molecular markers for human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] Heinz Höfler,et al. Mutations of the human E‐cadherin (CDH1) gene , 1998, Human mutation.
[14] Scott E Kern,et al. Focus on pancreas cancer. , 2002, Cancer cell.
[15] L. Saal,et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.
[16] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[17] Karla Kerlikowske,et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.
[18] A. Hollestelle,et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.
[19] D. Easton,et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.
[20] Chad J. Creighton,et al. MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research , 2007, Breast Cancer Research and Treatment.
[21] I. Bièche,et al. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer , 2000, Molecular carcinogenesis.
[22] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[23] J. Foekens,et al. The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. , 2008, Drug discovery today.
[24] R. Lidereau,et al. Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. , 1990, Cancer letters.
[25] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[26] D. Barnes,et al. Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.
[27] D Pinkel,et al. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. , 1998, Cancer research.
[28] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[29] K. Shokat,et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.
[30] J. Reis-Filho,et al. Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.
[31] S. Kern,et al. Mutation rate of MAP2K4/MKK4 in breast carcinoma , 2002, Human mutation.
[32] Tom Walsh,et al. Ten genes for inherited breast cancer. , 2007, Cancer cell.
[33] A. Chambers,et al. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? , 2009, Cancer research.
[34] C. Sherr. Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.
[35] T. Crook,et al. TP53 mutations in familial breast cancer: Functional aspects , 2003, Human mutation.
[36] H Clevers,et al. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. , 2001, Cancer research.
[37] Mieke Schutte,et al. Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.
[38] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[39] S. Merajver,et al. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines , 2008, Breast Cancer Research and Treatment.
[40] E. Paish,et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.
[41] John W M Martens,et al. Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.
[42] J. Herman,et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.
[43] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[44] J. Roth,et al. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. , 1976, Cancer research.
[45] D. Tong,et al. Comparison of p53 Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines , 2003, Breast Cancer Research and Treatment.
[46] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[47] R. Marais,et al. Melanoma biology and new targeted therapy , 2007, Nature.
[48] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Klijn,et al. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines , 2006, Breast Cancer Research and Treatment.